Phase I study of motixafortide +/- natalizumab to mobilize HSCs for gene therapy in SCD
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2026-01-12
Просмотров: 7
Описание:
Zachary Crees, MD, Washington University School of Medicine, St. Louis, MO, discusses a Phase I study (NCT05618301) demonstrating that the use of motixafortide, a CXCR4 inhibitor, both alone and in combination with natalizumab, a VLA-4 inhibitor, significantly improved the mobilization of hematopoietic stem cells (HSCs) for gene therapy in sickle cell disease (SCD), without increasing the risk of toxicities. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
